A meta-analysis of 18 trials found 5.63 kg average weight regain after stopping GLP-1 drugs, but real-world data from 188K patients shows 56% sustain some loss at 2 years.
The FDA approved semaglutide (Wegovy) as the first GLP-1 drug for MASH liver disease. The ESSENCE trial showed 62.9% of patients achieved disease resolution.
The FLOW trial cut kidney disease progression by 24% and death by 20%. Here is what the FDA approval means for the 37 million Americans with CKD.
A Swedish national cohort study found semaglutide associated with 42% lower risk of worsening mental illness. Here's what the evidence shows and what it doesn't.
A three-phase exercise program built for GLP-1 medication users, from first walks through full resistance training, with protein timing and nausea management strategies.
The WHO recommends long-term GLP-1 use for obesity. But only 4-year data exists, and half of patients stop by year one. What the research says about the forever drug question.
Multiple studies tracking hundreds of thousands of patients show GLP-1 drugs do not increase cancer risk. The thyroid concern from rodent studies has not translated to humans.
New research links GLP-1 medications to a 29% higher osteoporosis risk. Exercise and nutrition strategies can protect your bones while you lose weight.
The ASA reversed its GLP-1 surgery guidance from 'stop' to 'continue.' Current evidence and what to tell your surgical team.
A clinical trial reversed biological age markers by 3-5 years with semaglutide. We break down the evidence honestly.
A week-by-week breakdown of your first month on Ozempic, covering dose titration, side effect management, eating strategies, and when to call your doctor.
A meta-analysis of 18 trials found 5.63 kg average weight regain after stopping GLP-1 drugs, but real-world data from 188K patients shows 56% sustain some loss at 2 years.
The goal isn’t to be comfortable with change — it’s to be comfortable with one small change, on a schedule, held for a year.
We’re recording with NotebookLM. Expect a deep-dive and a short-form version of each issue’s best essays, delivered to your favorite podcast app when we launch.